Is it possible to control ageing and cancer? Most would say no but Mikhail Blagosklonny, believes otherwise. He has keen interest is the field of ontology and is an author of many publication such as aging hyper function theory and has written about cyclotherapy of cell and chemotherapeutic engineering. Using Rapamycin Mikhail believes cancer can be cured.
His interest in the field of medicine did not start now, he went to Pavlov State Medical University of St. Petersburg and got an MD in internal medicine and further got a PH. D from the same university in Experimental Medicine and Cardiology.
It was in 2009, that Mikhail joined Roswell Park Cancer Institute as a professor of ontology. Previously he was a senior scientist at Ordway Research Institute not before he was working as an associate professor of medicine at New York Medical College. He is well experienced, and his work is on cancer, anti-aging drugs, Biogerontology (Aging Mechanism), and cancer therapies that are targeted and aim at protecting the healthy cells from damage.
Mikhail Blagosklonny has a hypothesis on TOR Signaling potential role in cancer and aging. To extend life, he suggest the use of Rapamycin a drug used in cancer treatment and in longevity research he is seen as the most passionate about the use of Rapamycin. His research is vast and includes ontogenesis, tumor suppression, and cell cycle and also involves cellular and molecular biology to investigations that are clinical.
His interest in finding a cure for cancer makes him best suited to teach at Roswell so as to share his findings and passion with the young minds. Roswell Park Cancer Institute (RPCI) started way back in 1898 and is located in Buffalo, New York, its main focus being cancer research and treatment.
In 2010, Mikhail together with Andrei V.Gudkov went ahead to start Oncotarget a weekly peer-review open access medical journal. Oncotarget is a term covering all molecules, cellular function, and pathways common in cancer and aging, atherosclerosis, lymphocytes, cancer cells, and neurodegeneration. Thus the paper aim is to make results that are scientific rapid and widely available. The success of the Oncotarget provides more avenues for research and cancer cure development, and this gives hope to cancer patients.
Visit this page: gettingstronger.org